TABLE 2.

Levofloxacin pharmacokinetic parameters relative to MRSA 8043 and MRSA 8282 MICs and MPCs during in vitro system experiments^a

Simulation (Cavg ss)b	MRSA strain	Parameter during first 24 h					Steady-state parameter
						T0-24 MSW					T24ss MSW
125 mg every 24 h (0.68 μg/ml)	8043	2.66	28.1	0.80	8.46	47.5	3.22	32.9	0.97	9.90	53.1
	8282	2.64	28.2	0.72	7.70	46.1	3.05	32.4	0.83	8.84	57.5
250 mg every 24 h (1.33 μg/ml)	8043	5.48	56.8	1.65	17.1	55.7	6.17	63.3	1.86	19.1	56.0
	8282	5.33	56.6	1.46	15.5	58.9	5.99	64.1	1.64	17.5	62.2
500 mg every 24 h (2.62 μg/ml)	8043	10.7	113	3.22	34.0	41.9	12.1	127	3.64	38.2	37.0
	8282	10.6	114	2.89	31.1	45.9	11.8	125	3.22	34.2	41.7
750 mg every 24 h (3.93 μg/ml)	8043	16.1	164	4.85	49.5	22.2	18.9	188	5.69	56.8	19.6
	8282	16.2	167	4.43	45.7	28.3	18.5	188	5.05	51.5	24.4

^aExpressed as the means of results of two separate experiments. C_max1, C_max attained with the first dose; C_{max ss}, C_max at steady state; T_{0-24 MSW}, the percentage of time levofloxacin was in the MSW during the first 24-h period; T_24ssMSW, the percentage of time levofloxacin was in the MSW during a 24-h period at steady state.

^bC_{avg ss} for the simulated dosage regimens are expressed as the means of results of two separate experiments.